From Medscape Oncology

Coverage from the

Transplantation and Cellular Therapy (TCT) 2020:

Joint Meeting of the American Society for Blood and Marrow Transplantation (ASBMT) and the Center for International Blood and Marrow Transplant Research (CIBMTR)

February 19 - 23, 2020; Orlando, Florida

February 19 - 23, 2020 Orlando, Florida
  • TCT 2020 Geriatric Assessment Before HSCT Supports Good Outcomes Survival outcomes support the benefits of a geriatric assessment for patients age 70 and older with blood cancers who are candidates for hematopoietic stem cell transplants (HSCT).
  • TCT 2020 Caution: Higher Radiation Dose Linked to Worse NHL Outcomes Among patients with non-Hodgkin lymphoma who underwent reduced-intensity conditioning for stem cell transplant, overall survival was lower if they received a higher dose of radiation.

Conference News

Popular News from TCT 2019

  • Cord Blood Instead of Bone Marrow for HSCT for Blood Cancers Cord Blood Instead of Bone Marrow for HSCT for Blood Cancers Clinicians should get over their preconceptions about sourcing stem cells from cord blood for transplants in hematologic malignancies, as it can achieve good short- and long-term outcomes, says an expert in the field.
  • Ixazomib Shows Promise as Option for Chronic GVHD Ixazomib Shows Promise as Option for Chronic GVHD Patients with advanced chronic graft versus host disease who have failed multiple therapies may respond to ixazomib, a drug approved for second-line multiple myeloma treatment, say US scientists.
  • Treosulfan Better Than Busulfan in Prep for HSCT Treosulfan Better Than Busulfan in Prep for HSCT Older and sicker patients with acute myeloid leukemia undergoing stem cell transplant may fare better if they are given a treosulfan- rather than busulfan-based regimen, German scientists have shown.

Medscape Oncology© WebMD, LLC

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Previous Coverage